INTRODUCTION-In older adults, prior administration of 23-valent pneumococcal polysaccharide vaccine (PPSV23) blunts the opsonophagocytic antibody (OPA) response to subsequent administration of 13-valent pneumococcal conjugate vaccine (PCV13). To determine whether a higher dose of PCV13 could mitigate this effect in adults 55 through 74 years of age, we compared OPA responses to a double dose of PCV13 in persons previously vaccinated with PPSV23 with responses to a single dose of PCV13 in previously vaccinated persons, and with a single dose in PPSV23 naïve persons.
INTRODUCTION
In 2014, the Advisory Committee on Immunization Practices (ACIP) modified the longstanding recommendation for routine use of 23 valent pneumococcal polysaccharide vaccine (PPSV23) in adults 65 years of age and older to add routine administration of 13 valent pneumococcal conjugate vaccine (PCV13). (1) This decision was based in part on the results of a landmark randomized placebo controlled trial of PCV13 in approximately 85,000 pneumococcal vaccine naïve, immunocompetent adults 65 years of age and older in the Netherlands (CAPITA trial),(2) which found that PCV13 was effective in reducing the risks of vaccine-type community acquired pneumonia (efficacy 46%) and invasive pneumococcal disease (efficacy 75%).
evidence that prior administration of PPSV23 blunts the immune response to subsequent doses of PCVs, including PCV13, in adults.(3, 4) For immunocompetent adults ≥ 65 years who have received PPSV23 but not PCV13, a dose of PCV13 is recommended, to be given at least one year after the most recent dose of PPSV23. For those given the PPSV23-PCV13 sequence, the benefits of PCV13 vaccination observed in the CAPITA population of PPSV23 naïve persons may not be realized, due to the blunting of the immune response to PCV13 induced by the prior PPSV23 vaccination. An estimated 25% of immunocompetent adults 50 through 64 years of age in the United States have an indication for PPSV23 vaccination (5) and so could receive PPSV23 before they are recommended to receive PCV13.
We conducted a large dose ranging study of PCV13 vaccine that enrolled two groups of adults 55 through 74 years of age -those who had received PPSV23 three through seven years prior to enrollment and those who had never received PPSV23. The previously vaccinated subjects were randomized to receive either two 0.5 mL doses of PCV13 given concurrently or a single 0.5 mL dose of PCV13 and the OPA responses to the double dose were compared with the single dose to evaluate a dose effect. The vaccine naïve group received a single 0.5 mL dose of PCV13. The OPA responses to the double dose in the previously vaccinated group were compared with the responses to the single dose in the vaccine naïve group to evaluate the extent to which the higher dose could mitigate the effect of hyporesponsiveness due to prior PPSV23 exposure.
METHODS

Vaccine and administration
Each dose of PCV13 (Prevnar 13 ® , Pfizer, Philadelphia, PA), composed of saccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F , and 23F individually conjugated to nontoxic diphtheria toxin cross-reactive material 197 (CRM197), was supplied in a single 0.5 mL dose prefilled syringe and was administered by intramuscular injection in the deltoid. Subjects received either one 0.5 mL injection or two 0.5 mL injections, one in each arm, at the enrollment visit.
Study design
This open-label phase IIb study evaluated medically stable adults 55 through 74 years of age who had either never received PPSV23 or who had previously received exactly one prior dose of PPSV23, which was administered ≥3 and ≤7 years prior to enrollment. Enrollment into both groups was stratified by age group (55 through 64 years and 65 through 74 years) (Supplemental Figure 1 [flowchart, pending] ). The presence or absence of prior PPSV23 vaccination may have been presumptively ascertained by subject report but for all subjects was confirmed by review of primary source information, such as medical records or primary care or other provider report, covering at least the previous 10 years. All subjects provided written informed consent for study participation. Complete eligibility criteria are listed on clinicaltrials.gov. Subjects were enrolled at seven US sites between September 26, 2012 and March 3, 2015.
All PPSV23 naïve subjects received one 0.5 mL injection of PCV13. Previously vaccinated subjects were randomized within each age stratum with equal probability to receive one or two 0.5 mL injections of PCV13. The randomization sequence was generated using permutated block randomization with randomly selected block sizes of 2 or 4. Upon enrollment, each subject was assigned a randomization number from the electronic data entry system that corresponded to a treatment on a randomization list available at the study site.
After vaccination, subjects recorded oral temperature and solicited local and systemic reactogenicity information for 8 days (Day 1 [day of vaccination] through Day 8), using a memory aid. Unsolicited adverse events (AEs) were collected from the time of vaccination through Day 29 and serious adverse events (SAEs) were collected from the time of vaccination until the end of follow-up on Day 181.
Immunogenicity assays
Functional antibody titers were assessed by a fourfold multiplexed OPA killing assay performed at the University of Alabama at Birmingham as previously described (6) on samples obtained at baseline and on Days 29 and 181. Samples were identified only by specimen number to maintain blinding of laboratory personnel. OPA titers were determined for all of the PCV13 serotypes except serotype 3, which was not included in the testing because it is less immunogenic than other serotypes, and so a difference between study groups for this serotype was not likely to be seen, and because the OPA testing was done in batches of 4 serotypes so omitting one of the 13 serotypes allowed testing three batches instead of four. All PCV13 serotypes except serotype 6A are also contained in PPSV23.
Objectives
The safety objectives were to evaluate the acceptability of the safety profile of the single and double doses of PCV13 among subjects previously vaccinated with PPSV23, as measured by the frequency of solicited and unsolicited adverse events (AEs), and to specifically compare the frequency of injection site pain, tenderness, redness, and swelling between the two dose groups. For subjects who received a double dose, local reactogenicity was collected separately for each injected arm, and comparisons were based on the highest reported grade across both arms. An additional objective was to compare the frequency of injection site pain, tenderness, redness, and swelling following a single dose between subjects previously vaccinated with PPSV23 and vaccine naïve subjects.
The first of two primary immunogenicity objectives was to determine if, among subjects previously vaccinated with PPSV23, a double dose of PCV13 was statistically significantly more immunogenic at Day 29 than a single dose for at least some of the vaccine serotypes and was non-inferior for all of the 12 vaccine serotypes evaluated. The second primary immunogenicity objective was to determine if a double dose of PCV13 administered to subjects previously vaccinated with PPSV23 was non-inferior to a single dose administered to vaccine naïve subjects for the 12 vaccine serotypes at Day 29. The two secondary immunogenicity objectives included the same comparisons for samples obtained at Day 181.
Exploratory objectives included assessing the relationship between factors such as age and gender with vaccine response and with decline in antibody levels over time, by study group.
Data analysis
Sample size and analysis subsets-The two primary immunogenicity objectives for this study were each based on testing 12 related hypotheses, one for each serotype selected. Based on simulations that assumed at least one serotype was superior and a standard deviation of 2.0 on the natural log scale, a sample size of 280 evaluable subjects per group for each of the primary comparisons provided at least 80% power to meet the study objectives. Assuming a 5% drop out rate, the final planned sample size was 294 for each of the three study groups (Group I [vaccine naïve, 0.5 mL PCV13], Group IIA [previously vaccinated, 0.5 mL PCV13], and Group IIB [previously vaccinated, two 0.5 mL doses of PCV13]), for a total of 882 subjects.
All immunogenicity analyses reported are based on the intent-to-treat (ITT) analysis subset (n=883) which includes subjects who were vaccinated and had OPA results at baseline and at one or more post-vaccination time points.
Statistical analysis
Proportions of subjects reporting solicited AEs were compared using Fisher's Exact Test.
Comparisons of post-vaccination OPA titers between study groups were based on the lower bound of the 95% confidence interval (CI) of the log geometric mean ratio (GMR), with superiority defined by a lower bound > 1 and non-inferiority by a lower bound > 0.5. An analysis of variance tested for possible associations of Day 29 responses and covariates of interest such as gender, race, and age.
RESULTS
Demographics and characteristics
Demographic and baseline characteristics of subjects in the ITT subgroup are summarized in Table 1 and did not appreciably differ among the three study groups.
Safety
Solicited AEs-In general, systemic AEs were infrequent and most were reported as mild (Table 2) . Local AEs, particularly injection site pain and tenderness, were not uncommon and the highest proportions of moderate pain and tenderness were reported in Group IIB. All AEs were self-limited.
The percentage of subjects reporting solicited AEs was compared between groups. For Group I versus Group IIA, no statistically significant differences were identified. In contrast, in comparisons of Group IIA versus Group IIB, Group IIB was significantly more likely to report malaise, headache, chills, local pain, and local tenderness, as well as any systemic symptom, any local symptom, any moderate or severe systemic symptom and any moderate or severe local symptom.
Unsolicited AEs-Eight severe unsolicited non-serious AEs were reported. Only one of these, exacerbation of plantar fasciitis, with onset on the day of vaccination, was judged related to vaccination by the study investigator. There were 27 SAEs reported for 25 subjects, none of which were considered related to study vaccine.
Immunogenicity
Within each study group there were substantial variations in both baseline geometric mean titer (GMT) and in the magnitude of the OPA responses by serotype (Table 3) . Baseline titers were consistently higher in previously vaccinated compared with naïve subjects.
Group IIA versus Group I at Day 29-The OPA responses to a single dose of PCV13 were consistently lower in Group IIA (previously vaccinated) compared with Group I (naïve) for the 11 serotypes common to PCV13 and PPSV23, which is reflective of hyporesponsiveness induced by prior receipt of PPSV23. Among all subjects (both age groups), the non-inferiority threshold for Group IIA versus Group I was met for only 3 of the 12 serotypes tested (6A [not included in PPSV23], 14, and 19A) ( Figure 1 and Supplemental Table 1 ). Restricting to the younger age subgroup, the non-inferiority threshold was also met for serotype 6B while in the older age subgroup the non-inferiority threshold was not met for any serotype.
Group IIB versus Group IIA at Day 29-Among previously vaccinated subjects, OPA GMTs were consistently higher in Group IIB (double dose) than in Group IIA (single dose), indicating a dose response. Among all subjects, and in each of the age subgroups, the responses in Group IIB compared to Group IIA met the non-inferiority threshold for all 12 serotypes (Figure 2 and Supplemental Table 2 ). Among all subjects, the response in Group IIB also met the superiority threshold for 7 serotypes, while in the younger age subgroup this threshold was met for only 1 serotype and in the older age subgroup this threshold was met for 9 serotypes.
Group IIB versus Group I at Day 29-The OPA GMTs in Group IIB were consistently lower than in Group I. Among all subjects, the responses in Group IIB were non-inferior to those in Group I for the 9 serotypes: the 3 serotypes that met the non-inferiority threshold for Group IIA versus Group I and an additional 6 serotypes ( Figure 3 and Supplemental Table 3 ). In both the younger and older age subgroups the non-inferiority threshold was met for the same 8 serotypes. Thus, a double dose in previously vaccinated subjects produced responses that were more comparable to a single dose in naïve subjects than a single dose but that were not non-inferior for all tested serotypes.
Day 181 Responses-OPA GMTs declined substantially from Day 29 through Day 181 in all study groups but the patterns of between-group comparisons at Day 181 tended to correspond with those observed at Day 29 (Supplemental Tables 1-3 and Supplemental  Figures 2-4) . When comparing Day 181 responses among all subjects, Group IIA was noninferior to Group I for 8 serotypes, Group IIB was non-inferior to Group IIA for all 12 serotypes and was superior for 5 serotypes, and Group IIB was non-inferior to Group I for 10 serotypes.
Multivariate analyses-The multivariate analyses of variance for each of the Day 29 serotype specific OPA responses included the covariates of study group, age stratum, gender, and race (white vs non-white). In those analyses, Group I had significantly greater GMTs than Group IIA for all serotypes, Group I had significantly greater GMTs than Group IIB for all serotypes except 6A, and Group IIB had significantly greater GMTs than Group IIA for 9 serotypes. There was also an independent age effect, with the younger stratum having significantly higher titers for 9 serotypes, as well as a gender effect, with women having significantly higher titers for 10 serotypes, but not a race effect, with non-whites having higher titers for only one serotype.
DISCUSSION
In this large clinical trial evaluating both the effect of prior vaccination with PPSV23 on the immune response to subsequent PCV13 vaccination and the response to a double versus a single dose of PCV13 in previously vaccinated persons, we found, as with previous evaluations, that prior administration of PPSV23 blunts the OPA response to PCV13, a phenomenon known as hyporesponsiveness induced by plain polysaccharide antigens. (7) Among the subjects who received a single dose of PCV13, the Day 29 OPA responses in Group IIA (previously vaccinated) compared with Group I (vaccine naïve) achieved the threshold for non-inferiority for only 3 of the 12 serotypes among all subjects and for none of the serotypes in the older age subgroup. Among the previously vaccinated subjects there was evidence of a dose effect, with the Day 29 OPA responses in Group IIB (double dose of PCV13) compared to Group IIA (single dose) meeting the threshold for superiority for 7 serotypes among all subjects and for 9 serotypes in the older age subgroup. This dose effect led to greater comparability of responses between Group IIB and Group 1 than between Group IIA and Group I. The Day 29responses in Group IIB compared to Group I met the threshold for non-inferiority for 9 serotypes among all subjects and for 8 serotypes in the older age subgroup, suggesting that the higher dose could mitigate the effect of hyporesponsiveness.
Among previously vaccinated subjects, the double dose of PCV13 was associated with a higher frequency of solicited local and systemic AEs than the single dose, but the AEs tended to be mild or moderate and were self-limited.
The dose effect we observed is consistent with the findings of another, relatively small, dose ranging study of 7-valent PCV (PCV7) vaccine in adults 70 through 79 years of age previously vaccinated with PPSV23. That study evaluated PCV7 dosages of 0.5 mL, 1.0 mL, and 2.0 mL with 44 subjects per group. (8) In that study, the point estimates of the Day 29 OPA GMTs were higher after a dose of 1.0 mL than after the standard dose of 0.5 mL for five of the seven serotypes, although these differences were statistically significant for only two of those five. There was no further increase in OPA GMTs between the 1.0 mL and 2.0 mL dose groups.
The CAPITA study evaluated the standard dose of PCV13 in pneumococcal vaccine naïve adults 65 years of age and older. The use of the same formulation of PCV13 for both children and older adults was supported by a dose-ranging study in pneumococcal vaccine naïve older adults that found no consistent or statistically significant differences in OPA responses with doses higher than the pediatric dose.(9) There is no defined immunologic correlate of protection against pneumococcal infection in adults; therefore, it is not possible to determine whether the lower OPA responses observed in older adults previously vaccinated with PPSV23 are associated with diminished protection against vaccine-type pneumococcal infections. However, the validity of bridging from the CAPITA results to the likely benefit of the standard dose of PCV13 in previously vaccinated older adults is lessened by the demonstrably lower OPA responses to the standard dose of PCV13 in subjects previously vaccinated with PPSV23 (Group IIA) compared with PPSV23-naïve older adults (Group I).
The implication of these findings for consideration of alternate strategies for the use of PCV13 in adults is uncertain. First, the herd immunity effect from routine vaccination of children with PCVs (10) has greatly reduced the incidence of invasive pneumococcal disease due to PCV13 serotypes in persons 65 years of age or older --from 45 per 100,000 persons in 1999 to 6 per 100,000 persons in 2015. (11) In light of the known herd immunity effect, the 2014 ACIP recommendations indicated that routine use of PCV13 among adults aged ≥65 years will be reevaluated in 2018 and revised as needed, so it is possible that PCV13 may no longer be generally recommended for older adults. (1) Second, administration of a double dose of PCV13 for persons previously vaccinated with PPSV23 would be off-label and more expensive, which cannot be justified by a known benefit at this time. These findings do, however, have implications for vaccine development strategies, by highlighting limitations of a "one-size-fits-all" approach to adult vaccination, when vaccination benefits demonstrated in one group are not necessarily generalizable to other important population subgroups.
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